Data on IL36R inhibitor positive for AnaptysBio, says Cantor Fitzgerald

Cantor Fitzgerald analyst Eliana Merle views the first clinical data of an IL36R inhibitor in patients presented at EADV Congress as a positive read-through to AnaptysBio’s IL36R program. Anaptys’s second wholly owned clinical stage asset, ANB019, is an IL36R inhibitor in development for rare forms of psoriasis, Merle tells investors in a research note. She points out that data over the weekend from a competitor program, BI 655130, showed that IL36R inhibition can lead to clinically meaningful improvement in generalized pustular psoriasis. The analyst thinks this de-risks the IL36R mechanism ahead of initial patient data from ANB019 in GPP in early 2019. Merle keeps an Overweight rating on AnaptysBio with a $124 price target

https://thefly.com/landingPageNews.php?id=2791111